Skip to NavigationSkip to content

Atacand filed for heart failure in US

Published on 08/07/04 at 05:20pm

AstraZeneca has submitted its cardiovascular drug Atacand for an additional US licence to treat heart failure.

Atacand (candesartan) is one of the angiotensin receptor blocker (ARB) class competing in the crowded hypertension treatment area, and if granted, the new licence would help boost the brand's sales.

The company's submission is based on data from its CHARM study unveiled last year, which shows the drug cut deaths and serious illness in heart failure patients, something which no other drug in its class has demonstrated.

Adding Atacand to other hypertension treatments such as ACE inhibitors and beta-blockers was also shown to reduce the risk of cardiovascular death by an extra 15%.

Analysts say the licence would help AstraZeneca take on the market leading ARB, Novartis' Diovan, sales of which grew 46% to 2.4 billion in 2003, well ahead of Atacand's 32% growth to $750 million.

Novartis recently released results from its VALUE trial comparing Diovan with Pfizer's older hypertension drug Istin/Norvasc, but the results did not go all its way, the data suggesting the drugs were equally effective in preventing deaths due to cardiovascular disease.

Related articles:

Novartis rivals find VALUE in landmark Diovan trial 

Thursday, July 01, 2004

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches